Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Antipsychotic Not Certain Savior For Forest

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Cariprazine shows potential in top-line Phase II, as milnacipran PDUFA date – and firm’s patent cliff – grow near.

You may also be interested in...



Forest Ready To File Antipsychotic Cariprazine With Bipolar Mania Results

Success in a Phase III trial in schizophrenia, set to report in Q1 2012, would mean a double filing in mid-2012.

Forest Ready To File Antipsychotic Cariprazine With Bipolar Mania Results

Success in a Phase III trial in schizophrenia, set to report in Q1 2012, would mean a double filing in mid-2012.

Forest/Almirall’s Aclidinium Disappoints In Phase III COPD Trial

Bronchodilatory effect of aclidinium was statistically significant compared to placebo, but lower than seen in previous studies.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

EU CHMP Opinions And MAA Updates

As New Tech Emerges For Early Research, FDA Chief Scientist Says Diversity Must Start In Preclinical Development

Pilot Phase Of Operation Warp Speed For Rare Diseases Beginning Soon

Platform Technology Designation A Gene Therapy Opportunity, OTP Director Verdun Says

See All
UsernamePublicRestriction

Register

PS068423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By